Quest Diagnostics Incorporated $DGX Stock Sold by Boston Partners

Quest Diagnostics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Partners cut its Quest Diagnostics stake by 2.2%, selling 104,521 shares in the third quarter; it still held 4.64 million shares valued at about $1.08 billion.
  • Quest Diagnostics beat quarterly earnings and revenue estimates, reporting $3.00 EPS and $3.10 billion in revenue; revenue rose 10% year over year.
  • The company declared a quarterly dividend of $0.86 per share, equivalent to a 1.3% annual yield. Analysts’ consensus rating was “Moderate Buy,” with a $248.70 average target price.
  • Interested in Quest Diagnostics? Here are five stocks we like better.

Boston Partners lessened its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,639,952 shares of the medical research company's stock after selling 104,521 shares during the period. Quest Diagnostics comprises 0.9% of Boston Partners' portfolio, making the stock its 20th largest holding. Boston Partners owned approximately 4.22% of Quest Diagnostics worth $1,080,534,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Meeder Asset Management Inc. raised its holdings in Quest Diagnostics by 496.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 167 shares of the medical research company's stock valued at $39,000 after acquiring an additional 139 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of Quest Diagnostics by 5.5% during the 3rd quarter. Global Retirement Partners LLC now owns 2,667 shares of the medical research company's stock worth $622,000 after purchasing an additional 139 shares during the period. Cibc World Market Inc. boosted its holdings in shares of Quest Diagnostics by 28.5% during the third quarter. Cibc World Market Inc. now owns 9,623 shares of the medical research company's stock worth $2,243,000 after purchasing an additional 2,135 shares during the last quarter. HighTower Advisors LLC boosted its holdings in shares of Quest Diagnostics by 0.6% during the third quarter. HighTower Advisors LLC now owns 68,110 shares of the medical research company's stock worth $15,874,000 after purchasing an additional 418 shares during the last quarter. Finally, Intech Investment Management LLC grew its position in shares of Quest Diagnostics by 13.3% in the third quarter. Intech Investment Management LLC now owns 23,090 shares of the medical research company's stock valued at $5,382,000 after purchasing an additional 2,715 shares during the period. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Stock Performance

NYSE:DGX opened at $259.17 on Thursday. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $263.19. The firm has a 50-day moving average of $242.61 and a two-hundred day moving average of $216.71. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.70 and a quick ratio of 1.58. The stock has a market cap of $28.51 billion, a P/E ratio of 25.81, a PEG ratio of 2.30 and a beta of 0.55.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The company had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the business earned $2.60 EPS. Quest Diagnostics's revenue for the quarter was up 10.0% compared to the same quarter last year. On average, research analysts expect that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be paid a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Tuesday, January 12th. Quest Diagnostics's dividend payout ratio (DPR) is 34.26%.

Insider Buying and Selling

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total value of $2,427,200.00. Following the completion of the transaction, the chief executive officer owned 122,423 shares of the company's stock, valued at $29,714,510.56. The trade was a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patrick Plewman sold 11,717 shares of Quest Diagnostics stock in a transaction on Monday, November 9th. The stock was sold at an average price of $257.34, for a total transaction of $3,015,252.78. Following the completion of the transaction, the senior vice president directly owned 14,684 shares of the company's stock, valued at approximately $3,778,780.56. This represents a 44.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 79,478 shares of company stock worth $19,794,031. 0.88% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DGX. UBS Group reiterated a "neutral" rating and issued a $250.00 target price on shares of Quest Diagnostics in a research note on Monday, October 19th. Weiss Ratings upgraded Quest Diagnostics from a "buy (a)" rating to a "buy (a+)" rating in a report on Wednesday, October 21st. Argus set a $260.00 price target on Quest Diagnostics in a report on Wednesday, July 29th. Robert W. Baird set a $262.00 price objective on shares of Quest Diagnostics in a research note on Friday, October 23rd. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $245.00 price objective on shares of Quest Diagnostics in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Quest Diagnostics has a consensus rating of "Moderate Buy" and a consensus target price of $248.70.

Check Out Our Latest Report on Quest Diagnostics

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics NYSE: DGX is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Featured Articles

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX - Free Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Quest Diagnostics Right Now?

Before you consider Quest Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.

While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines